Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

C.R. Bard (BCR)

C.R. Bard (BCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

C.R. Bard 730 CENTRAL AVE MURRAY HILL NJ 07974 USA

www.crbard.com P: 908-277-8000

Description:

C. R. Bard, Inc., together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide. The company offers vascular products, such as percutaneous transluminal angioplasty catheters, chronic total occlusion catheters, guidewires, fabrics, meshes, introducers, and accessories; valvuloplasty balloons; peripheral vascular stents, self-expanding and balloon-expandable covered stents, and vascular grafts; vena cava filters; biopsy devices; and a range of minimally invasive devices for the treatment of peripheral vascular and end-stage renal diseases. It also provides urology products, including Foley catheters to reduce the rate of urinary tract infections; fecal incontinence products; brachytherapy devices and radioactive seeds for the treatment of prostate cancer; intermittent urinary drainage catheters, and urine monitoring and collection systems etc.

Key Statistics

Overview:

Market Capitalization, $K 24,144,082
Shares Outstanding, K 72,890
Annual Sales, $ 3,714 M
Annual Net Income, $ 531,400 K
Last Quarter Sales, $ 989,800 K
Last Quarter Net Income, $ 93,600 K
60-Month Beta 0.52
% of Insider Shareholders 0.80%
% of Institutional Shareholders 79.11%

Growth:

1-Year Return 48.91%
3-Year Return 97.78%
5-Year Return 228.19%
5-Year Revenue Growth 28.23%
5-Year Earnings Growth 60.78%
5-Year Dividend Growth 35.14%

Per-Share Information:

Most Recent Earnings 3.02 on 10/25/17
Next Earnings Date 01/25/18
Earnings Per Share ttm 11.58
EPS Growth vs. Prev Qtr 3.42%
EPS Growth vs. Prev Year 14.39%
Annual Dividend Rate, $ 0.78
Annual Dividend Yield 0.23%
Most Recent Dividend 0.260 on 07/20/17
Next Ex-Dividends Date 07/20/17
Dividend Payable Date 08/04/17
Dividend Payout Ratio 8.70%
Most Recent Split 2-1 on 06/01/04

BCR Ratios

Ratio
Price/Earnings ttm 28.77
Price/Earnings forward 27.86
Price/Earnings to Growth 2.53
Return-on-Equity % 48.28%
Return-on-Assets % 16.23%
Profit Margin % 14.31%
Debt/Equity 0.98
Price/Sales 6.54
Price/Cash Flow 24.58
Price/Book 11.97
Book Value/Share 27.68
Interest Coverage 8.74
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar